Andrew Schwendenman net worth and biography

Andrew Schwendenman Biography and Net Worth

CAO of Replimune Group

Andrew Schwendenman is currently serving as the Treasurer & Chief Accounting Officer at Replimune Group, Inc. He previously worked as the Controller at Carbonite, Inc. from 2016 to 2020.

Mr. Schwendenman completed his undergraduate degree at the University of Massachusetts.

What is Andrew Schwendenman's net worth?: The estimated net worth of Andrew Schwendenman is at least $283,343.58 as of May 16th, 2024. Schwendenman owns 38,238 shares of Replimune Group stock worth more than $283,344 as of May 13th. This net worth approximation does not reflect any other investments that Schwendenman may own. Learn More about Andrew Schwendenman's net worth.
How old is Andrew Schwendenman?: Schwendenman is currently 48 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Andrew Schwendenman's age.
How do I contact Andrew Schwendenman?: The corporate mailing address for Schwendenman and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Andrew Schwendenman's contact information.
Has Andrew Schwendenman been buying or selling shares of Replimune Group?: Andrew Schwendenman has not been actively trading shares of Replimune Group within the last three months. Most recently, Andrew Schwendenman sold 2,298 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a transaction totalling $14,868.06. Following the completion of the sale, the chief accounting officer now directly owns 38,238 shares of the company's stock, valued at $247,399.86. Learn More on Andrew Schwendenman's trading history.
Who are Replimune Group's active insiders?: Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.
Are insiders buying or selling shares of Replimune Group?: During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.
Information on this page was last updated on 12/16/2024.

Andrew Schwendenman Insider Trading History at Replimune Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2024	Sell	2,298	$6.47	$14,868.06	38,238

Andrew Schwendenman Buying and Selling Activity at Replimune Group

Replimune Group Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $7.41

$7.40

$7.95

50 Day Range

MA: $9.27

$6.92

$12.11

2 Week Range

Now: $7.41

$4.92

$17.00

Volume

663,362 shs

Average Volume

899,837 shs

Market Capitalization

$570.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Andrew Schwendenman Biography and Net Worth

What is Andrew Schwendenman's net worth?

How old is Andrew Schwendenman?

How do I contact Andrew Schwendenman?

Has Andrew Schwendenman been buying or selling shares of Replimune Group?

Who are Replimune Group's active insiders?

Are insiders buying or selling shares of Replimune Group?